Suscripción a Biblioteca: Guest
Portal Digitalde Biblioteca Digital eLibros Revistas Referencias y Libros de Ponencias Colecciones
Critical Reviews™ in Immunology
Factor de Impacto: 1.404 Factor de Impacto de 5 años: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Imprimir: 1040-8401
ISSN En Línea: 2162-6472

Volumes:
Volumen 40, 2020 Volumen 39, 2019 Volumen 38, 2018 Volumen 37, 2017 Volumen 36, 2016 Volumen 35, 2015 Volumen 34, 2014 Volumen 33, 2013 Volumen 32, 2012 Volumen 31, 2011 Volumen 30, 2010 Volumen 29, 2009 Volumen 28, 2008 Volumen 27, 2007 Volumen 26, 2006 Volumen 25, 2005 Volumen 24, 2004 Volumen 23, 2003 Volumen 22, 2002 Volumen 21, 2001 Volumen 20, 2000 Volumen 19, 1999 Volumen 18, 1998 Volumen 17, 1997 Volumen 16, 1996 Volumen 15, 1995 Volumen 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v21.i1-3.70
18 pages

The Potential of CpG Oligodeoxynucleotides as Mucosal Adjuvants

Risini D. Weeratna
Coley Pharmaceutical Group, Ottawa
Paul J. Payette
Coley Pharmaceutical Group, Ottawa; Loeb Health Research Institute, Ottawa; Faculties of Health Sciences and Medicine, University of Ottawa
Heather L. Davis
Coley Pharmaceutical Group, Ottawa; Loeb Health Research Institute, Ottawa; Faculties of Health Sciences and Medicine, University of Ottawa

SINOPSIS

The development of mucosal vaccines for humans has been hindered by the lack of safe yet effective mucosal adjuvants. Bacterial toxins are commonly used as adjuvants in animal models, but they are too toxic for use in humans. A novel class of adjuvant is CpG DNA, which contains unmethylated CpG dinucleotides in particular base contexts (CpG motifs). CpG DNA is most often coadministered with antigen in the form of synthetic oligodeoxynucleotides (CpG ODN), which are made with a nuclease-resistant phosphorothioate backbone. The vast majority of studies using CpG DNA as adjuvant have been with parenteral delivery; recently, however, mucosal immunization with CpG DNA as adjuvant has also been shown to induce both systemic (humoral and cellular) and mucosal antigen-specific immune responses. This review will highlight the recent uses of CpG DNA as an adjuvant at mucosal surfaces.


Articles with similar content:

Novel Strategies Using DNA for the Induction of Mucosal Immunity
Critical Reviews™ in Immunology, Vol.19, 1999, issue 4
Heather L. Davis, Michael J. McCluskie
Microparticles and Nanoparticles as Delivery Systems for DNA Vaccines
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.20, 2003, issue 2&3
Zhengrong Cui, Russell J. Mumper
Mucosal Immunization: A Review of Strategies and Challenges
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 4
Mohan N. Rathi, Hinal Patel, Chetan Yewale, Ambikanandan Misra
Structuring Polymers for Delivery of DNA-Based Therapeutics: Updated Insights
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.29, 2012, issue 6
Suresh P. Vyas, Shailja Tiwari, Madhu Gupta
Current Nanotechnological Strategies for Effective Delivery of Bioactive Drug Molecules in the Treatment of Tuberculosis
Critical Reviews™ in Therapeutic Drug Carrier Systems, Vol.31, 2014, issue 1
Mandeep Kaur, Goutam Rath, Tarun Garg, Amit Kumar Goyal